CD8A and glioblastoma: Xuan et al. showed that inhibition of the CLOCK-OLFML3-HIF1a-LGMN-CD162 axis reduces immunosuppressive microglia and increases CD8+ T cell infiltration, activation, and cytotoxicity within GBM, as well as creates a synergy with anti-PD-1 therapy [49].